Kamra Deepak - Net Worth and Insider Trading

Kamra Deepak Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kamra Deepak owns 3 companies in total, including Amicus Therapeutics Inc (FOLD) , EPIRUS Biopharmaceuticals Inc (EPRSQ) , and DexCom Inc (DXCM) .

Click here to see the complete history of Kamra Deepak’s form 4 insider trades.

Insider Ownership Summary of Kamra Deepak

Ticker	Comapny	Transaction Date	Type of Owner
FOLD	Amicus Therapeutics Inc	2007-05-30	10 percent owner
EPRSQ	EPIRUS Biopharmaceuticals Inc	2005-11-15	10 percent owner
DXCM	DexCom Inc	2005-04-13	10 percent owner

Kamra Deepak Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kamra Deepak Ownership Network

Ownership Network List of Kamra Deepak

No Data

Ownership Network Relation of Kamra Deepak

Kamra Deepak Owned Company Details

What does Amicus Therapeutics Inc do?

Who are the key executives at Amicus Therapeutics Inc?

Kamra Deepak is the 10 percent owner of Amicus Therapeutics Inc. Other key executives at Amicus Therapeutics Inc include director & President and CEO Bradley L Campbell , director & Executive Chairman John F Crowley , and Chief People Officer David Michael Clark .

Amicus Therapeutics Inc (FOLD) Insider Trades Summary

Over the past 18 months, Kamra Deepak made no insider transaction in Amicus Therapeutics Inc (FOLD). Other recent insider transactions involving Amicus Therapeutics Inc (FOLD) include a net sale of 623,732 shares made by John F Crowley , a net sale of 260,446 shares made by Bradley L Campbell , and a net sale of 51,919 shares made by David Michael Clark .

In summary, during the past 3 months, insiders sold 75,014 shares of Amicus Therapeutics Inc (FOLD) in total and bought 0 shares, with a net sale of 75,014 shares. During the past 18 months, 1,222,514 shares of Amicus Therapeutics Inc (FOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,222,514 shares.

Amicus Therapeutics Inc (FOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amicus Therapeutics Inc Insider Transactions

No Available Data

What does EPIRUS Biopharmaceuticals Inc do?

Who are the key executives at EPIRUS Biopharmaceuticals Inc?

Kamra Deepak is the 10 percent owner of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Financial Officer Thomas A. Shea , Chief Business Officer Vincent Aurentz , and director & Chief Executive Officer Amit Munshi .

EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

EPIRUS Biopharmaceuticals Inc Insider Transactions

No Available Data

What does DexCom Inc do?

Who are the key executives at DexCom Inc?

Kamra Deepak is the 10 percent owner of DexCom Inc. Other key executives at DexCom Inc include * Matthew Vincent Dolan , EVP & Chief Legal Officer Micheal Jon Brown , and Chief Human Resources Officer Sadie Stern .

DexCom Inc (DXCM) Insider Trades Summary

Over the past 18 months, Kamra Deepak made no insider transaction in DexCom Inc (DXCM). Other recent insider transactions involving DexCom Inc (DXCM) include a net sale of 20,032 shares made by Steven Robert Pacelli , a net sale of 31,284 shares made by Sadie Stern , and a net sale of 329,692 shares made by Kevin R Sayer .

In summary, during the past 3 months, insiders sold 213,540 shares of DexCom Inc (DXCM) in total and bought 0 shares, with a net sale of 213,540 shares. During the past 18 months, 561,799 shares of DexCom Inc (DXCM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 561,799 shares.

DexCom Inc (DXCM)'s detailed insider trading history can be found in Insider Trading Tracker table.

DexCom Inc Insider Transactions

No Available Data

Kamra Deepak Mailing Address

Above is the net worth, insider trading, and ownership report for Kamra Deepak. You might contact Kamra Deepak via mailing address: C/o Canaan Partners, 285 Riverside Avenue, Suite 250, Westford Ct 06880.

Discussions on Kamra Deepak

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.